Mantle Cell Lymphoma (MCL) Recruiting Phase 1 Trials for Ibrutinib (DB09053)

Also known as: Lymphoma, Mantle-Cell / Mantle Cell Lymphoma / Mantle-Cell Lymphoma / Lymphoma, Mantle- Cell / Lymphoma, Mantle Cell / Mantle-Cell Lymphomas / B cell lymphoma / Centrocytic lymphoma / Mantle cell lymphoma NOS / Mantle cell lymphomas

IndicationStatusPhase
DBCOND0071979 (Mantle Cell Lymphoma (MCL))Recruiting1
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT02419560Optimal Dose Finding Study ABT-199 and Ibrutinib in MCLTreatment
NCT03684694Safety and Antitumor Activity Study of Loncastuximab Tesirine + Ibrutinib in Diffuse Large B-Cell or Mantle Cell LymphomaTreatment
NCT02446236Dose Finding Study of Ibrutinib Plus Lenalidomide / Rituximab in Relapsed or Refractory Mantle Cell LymphomaTreatment